Cyclobenzaprine Hydrochloride
Indications
Registered South African indications:
- Muscle spasm
Cautions
Contraindications
- Hypersensitivity to the active ingredient or any of its excipients
- Dysrhythmias
- Conduction disturbances
- Congestive heart failure
- Recent myocardial infarction
- Hyperthyroidism
- Coadministration with monoamine oxidase inhibitors or use within 14 days of their use
Cautions
- Pregnancy
- Breastfeeding
- Hepatic impairment
- Elderly
- Urinary retention
- Angle-closure glaucoma
- Increased intraocular pressure
- History of epilepsy
- May impair the ability to drive and operate machinery
Adult dosage
Forms avail. in SA and covered in this monograph: cap
Muscle spasm associated with acute musculoskeletal conditions
-
Oral (cap): 15mg; dly; Max: 30mg/24hrs
Do not use longer than 2-3 weeks
Paediatric dosage
Not established for use in children
Special populations
Pregnancy
- Caution; no evidence of risk in studies
- The safe use of cyclobenzaprine hydrochloride has not been established in pregnancy. Animal studies have not demonstrated a foetal risk
Breastfeeding
- Caution; not recommended
- Excretion of cyclobenzaprine in breast milk is unknown. The potential risk of adverse effects to breastfeeding infants cannot be excluded, therefore, caution is recommended when administering to breastfeeding mothers
Renal Impairment
Hepatic Impairment
- Caution; no dose adjustment recommended
Not recommended; regardless of the severity of hepatic impairment (mild, moderate, severe)
Elderly
- Caution; no dose adjustment recommended
Not recommended; regardless of the severity of hepatic impairment (mild, moderate, severe)
Porphyria Information
Drugs in Sport
- Permitted - No warnings
Adverse reactions
Central Nervous System Disorders
- Seizures
- Ataxia
- Vertigo
- Dysarthria
- Tremors
- Hypertonia
- Muscle twitching
- Disorientation
- Insomnia
- Depressed mood
- Abnormal sensations
- Anxiety
- Agitation
- Psychosis
- Abnormal thinking and dreaming
- Hallucinations
- Excitement
- Paresthesia
- Diplopia
- Tinnitus
- Decreased or increased libido
- Abnormal gait
- Delusions
- Aggressive behaviour
- Paranoia
- Peripheral neuropathy
- Bell’s palsy
- Alteration in EEG patterns
- Extrapyramidal symptoms
Cardiovascular Disorders
- Tachycardia
- Dysrhythmia
- Vasodilatation
- Palpitation
- Hypotension
- Syncope
- Chest pain
- Myocardial infarction
- Heart block
- Stroke
- Hypertension
- Oedema
Respiratory Disorders
- Dyspnoea
Gastrointestinal Disorders
- Vomiting
- Anorexia
- Diarrhoea
- Gastrointestinal pain
- Gastritis
- Thirst
- Flatulence
- Ageusia
- Paralytic ileus
- Tongue discolouration
- Stomatitis
- Parotid swelling
Hepatobiliary Disorders
- Abnormal hepatic function tests
- Hepatitis
- Jaundice
- Cholestasis
Genitourinary Disorders
- Urinary frequency
- Urinary retention
- Impaired urination
- Dilatation of urinary tract
- Impotence
- Testicular swelling
- Gynaecomastia
- Breast enlargement
- Galactorrhea
Endocrine & Metabolic Disorders
- Disturbances of blood glucose levels
- Weight gain or loss
- Syndrome of inappropriate antidiuretic hormone secretion
Musculoskeletal Disorders
- Local weakness
- Myalgia
Skin and Subcutaneous Tissue Disorders
- Photosensitisation
- Alopecia
- Pruritus
- Facial oedema
- Urticarial
- Rash
Immune, Blood and Lymphatic System Disorders
- Purpura
- Bone marrow depression
- Leucopenia
- Eosinophilia
- Thrombocytopenia
- Anaphylaxis
- Angioedema
Interactions
- Monoamine oxidase inhibitors
- Central nervous system depressants
- Guanethidine
- Tramadol
- Anticholinergic medication
Monitoring
None routine
Mechanism of action
Cyclobenzaprine acts primarily within the central nervous system at the level of the brain stem. However, it does seem to act to some degree at the level of the spinal cord, which may contribute to its overall skeletal muscle relaxant activity. The net effect of cyclobenzaprine is a reduction of tonic somatic motor activity
Dosage forms
- Capsule
Formulation
Capsule 15mg
- Myprocam (Adcock) originator
Capsule 30mg
- Myprocam (Adcock) originator
References
1. Myprocam 15mg, 30mg extended release capsule, Adcock Ingram Ltd:Date of registration: 6 Mar 2014 [https://drive.google.com/drive/u/0/folders/1TO3Wm7Nu5Rrt9F42qJRf5TWq7rrhw5to] 2. Drugs.com: Cyclobenzaprine; Downloaded online 28 Nov 2018 [https://drive.google.com/drive/u/0/folders/1TO3Wm7Nu5Rrt9F42qJRf5TWq7rrhw5to] 3. S Afr Pharm J 2015 Vol 82 No 5 - Myprocam - Drug Info new product focus 4. EMG-Clinical Pharmacologist - Literature Review. 5. Amrix (cyclobenzaprine) [prescribing information]. North Wales, PA: Teva Pharmaceuticals, Inc; May 2016. 6. Herman CR, Schiffman EL, Look JO, Rindal DB. The effectiveness of adding pharmacologic treatment with clonazepam or cyclobenzaprine to patient education and self-care for the treatment of jaw pain upon awakening: a randomized clinical trial. J Orofac Pain. 2002;16(1):64-70.. 7. UpToDate; Cyclobenzaprine; Accessed online 11 Dec 2018 [https://www.uptodate.com/contents/cyclobenzaprine-drug-information?search=cyclobenzaprine&source=panel_search_result&selectedTitle=1~36&usage_type=panel&kp_tab=drug_general&display_rank=1] 8. NAPOS The Drug Database for Acute Porphyria: M03BX08 Cyclobenzaprine; Accessed online 11 Dec 2018 [http://www.drugs-porphyria.org/languages/UnitedKingdom/s3.php?l=gbr&atc_code=M03BX08] 9. South African Institute for Drug-Free Sport; Myprocam; Accessed online 11 Dec 2018 [http://www.drugfreesport.org.za/online-medication-check/] 10. Afritox; Cyclobenzaprine hydrochloride; Accessed online: 30 June 2020 [http://www.afritox.co.za/hp/SingleToxin/SingleToxin.aspx?SingleToxinID=20269] ****There is no SPC avail for this product *****recently launched in SA (2014 / 2015)
Brands & products
4 products · stale NAPPI snapshot · refreshed 5/28/2026 · 159 days oldCapsulesGeneric· 2 products
from R23.57/unit| Product | Strength | Pack | Sched | SEP | Unit | Disp fee | NAPPI |
|---|---|---|---|---|---|---|---|
| Pribemak 15 | 15 mg | 30 | S5 | R707.20 | R23.57 | R188.50 | 3010186001 |
| Pribemak 30 | 30 mg | 30 | S5 | R1072.15 | R35.74 | R242.19 | 3010187001 |
SrcGeneric· 2 products
from R24.33/unit| Product | Strength | Pack | Sched | SEP | Unit | Disp fee | NAPPI |
|---|---|---|---|---|---|---|---|
| Myprocam | 15 mg | 30 | S5 | R729.93 | R24.33 | R191.85 | 720360001 |
| Myprocam | 30 mg | 30 | S5 | R1108.54 | R36.95 | R247.55 | 720361001 |
- Myprocam
Medical aid coverage
data not yet integrated- Comprehensive Series—
- Executive Plan—
- KeyCare Series—
- Priority Series—
- Saver Series—
Formulary scraper pending — coverage tier, co-pay and authorisation requirements will appear here once data is ingested.
- BonClassic—
- BonComprehensive—
- BonEssential—
- BonFit Select—
- BonSave—
- BonStart—
Formulary scraper pending — coverage tier, co-pay and authorisation requirements will appear here once data is ingested.
- Beryl—
- Emerald—
- Onyx—
- Ruby—
- Sapphire—
- Tanzanite One—
Formulary scraper pending — coverage tier, co-pay and authorisation requirements will appear here once data is ingested.
- Aquarium Option—
- Efficiency Option—
- Marine Option—
Formulary scraper pending — coverage tier, co-pay and authorisation requirements will appear here once data is ingested.